SEC Tracker
Get the app

Apnimed APMD

Apnimed Q2 FY26: revenue $12.1M

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Apnimed reported for Q2 FY26, the quarter ended Jun 30, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$12.1MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income$125.9MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Cash and cash equivalents$172.8MNo year-earlier figure tagged10-Q balance sheet, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Apnimed files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Merus MRUS
  2. Editas Medicine EDIT public float $191M, Jun 30, 2025
  3. XOMA Royalty XOMA public float $168M, Jun 30, 2025
  4. Abeona Therapeutics ABEO public float $273M, Jun 30, 2025
  5. Stoke Therapeutics STOK public float $592M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.